Table 3.
Adjusted risk difference (95% CI) of PTH >600 pg/mL 9–12 months after HD initiation
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | ||
|---|---|---|---|---|---|---|
| n (%) | Unadjusted | + Region, phase | + Age, sex, black race | + 13 summary comorbidities | + Albumin, Hgb, catheter, BMI | |
| PTH prior to HD start (pg/mL) | ||||||
| <50 | 128 (5) | −2.6 (−8.2, 3.1) | −3.5 (−9.1, 2.2) | −2.7 (−8.3, 2.9) | −2.8 (−8.4, 2.8) | −2.7 (−8.4, 2.9) |
| 50–100 | 248 (9) | −3.9 (−8.3, 0.4) | −3.9 (−8.2, 0.4) | −3.8 (−8.1, 0.4) | −3.9 (−8.1, 0.4) | −4.0 (−8.3, 0.3) |
| 100–150 | 254 (9) | −2.3 (−6.5, 2.0) | −2.5 (−6.7, 1.8) | −2.1 (−6.3, 2.2) | −2.3 (−6.6, 1.9) | −2.4 (−6.7, 1.8) |
| 150–300 | 815 (30) | 0 (Ref.) | 0 (Ref.) | 0 (Ref.) | 0 (Ref.) | 0 (Ref.) |
| 300–450 | 491 (18) | 2.8 (−0.5, 6.2) | 2.8 (−0.6, 6.2) | 2.1 (−1.3, 5.4) | 2.1 (−1.3, 5.5) | 2.2 (−1.2, 5.6) |
| 450–600 | 330 (12) | 8.6 (4.7, 12.4) | 8.2 (4.4, 12.1) | 7.1 (3.3, 11.0) | 7.2 (3.3, 11.0) | 7.2 (3.4, 11.1) |
| >600 | 462 (17) | 21.9 (18.5, 25.4) | 21.4 (17.9, 24.9) | 19.0 (15.4, 22.5) | 19.0 (15.4, 22.5) | 19.2 (15.6, 22.8) |
Linear probability models, using a random facility intercept to account for clustering. Adjusted difference in the probability (shown as percentage) of PTH >600 pg/mL at 9−12 months after HD initiation estimated across levels of PTH measured immediately prior to HD initiation (reference: PTH 150–300 pg/mL immediately prior to HD initiation). In other words, the absolute risk of a PTH >600 pg/mL at 9–12 months was 19 percentage points higher for patients with a baseline PTH >600 pg/mL versus the reference group of baseline PTH 150–300 pg/mL (absolute risk in reference group: 7%). Hgb, haemoglobin; BMI, body mass index.